April 6, 2024 Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did not show a significant benefit in reducing overall heart failure hospitalizations or death from any cause, according to a study presented at the American College of Cardiologys Annual Scientific Session. However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack.
Javed Butler, MD
Despite falling short of its primary endpoint, results from the EMPACT-MI trial found that people who took empagliflozin had a significantly lower risk of certain outcomes directly related to heart failure, including first hospitalization for heart failure, total hospitalization for heart failure and a composite of heart failure hospitalization and death from heart failure, without any increased risk of adverse events.
We found that empagliflozin did not reduce mortality after a heart attack but did reduce the risk of heart failure after heart attack, said Javed Butler, MD, president of the Baylor Scott and White Research Institute in Dallas, distinguished professor of medicine at the University of Mississippi in Jackson, Mississippi, and the studys lead author. To have a 25% to 30% reduction in heart failure hospitalizations is pretty clinically meaningful, but if you put it together with all-cause mortality, it was not a positive study for our primary endpoint.
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. As evidence has mounted pointing to their benefits in reducing heart failure and other forms of heart disease, researchers have sought to determine whether these drugs could help to prevent heart failure even in people without diabetes or chronic kidney disease.
A heart attack can damage the heart muscle in ways that sometimes lead to heart failure, a condition in which the heart becomes too weak or too stiff to effectively pump blood throughout the body. The EMPACT-MI trial was designed to determine whether SGLT-2 inhibitors could safely help to prevent heart failure and reduce mortality in people with a high risk of heart failure following a heart attack.
The study enrolled 6,522 people treated for acute myocardial infarction at 451 centers in 22 countries. Participants had no history of heart failure but had at least one heart failure risk factor in addition to signs of potential heart dysfunction as indicated by a newly lowered left ventricle ejection fraction to below45% and/or signs or symptoms of congestion requiring treatment. About 32% had Type 2 diabetes. On average, participants were 64 years old and approximately 25% were women and 84% were White. Within 14 days of being admitted to the hospital for a heart attack, half of the participants were randomly assigned to receive empagliflozin at a dose of 10 mg daily, while the other half received a placebo. Researchers tracked outcomes for a median of just under 18 months.
The studys primary composite endpoint occurred in 8.2% of those who received empagliflozin and 9.1% of those receiving a placebo, a difference that was not statistically significant. There was also no difference in the rate of death from any cause, which occurred in 5.2% of those receiving empagliflozin and 5.5% of the control group.
All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin. For example, those receiving empagliflozin were 23% less likely to experience a first heart failure hospitalization and 33% less likely to experience any heart failure hospitalizationincluding recurrent hospitalizationscompared with those taking a placebo. The composite rate of total heart failure hospitalizations and death from heart failure was also 31% lower among those receiving empagliflozin.
Among patients who were not taking common heart failure therapies such as diuretics, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor/neprilysin inhibitor (ARNI) at the time of their initial hospital discharge, those taking empagliflozin were significantly less likely to start such therapies within six months compared with those taking a placebo.
In terms of heart failure outcomes, the data is not only strong, but its consistent with what weve found over the past 10 years in yet another population, Butler said. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.
While as a pragmatic trial design to simplify trial procedures and make it easier on both the participants and the sites, the study had limitations that may have influenced the findings, researchers said. For example, because outcomes were not adjudicated by independent reviewers, outpatient heart failure events were not formally captured as part of the primary endpoint. However, researchers said data on outpatient heart failure visits were collected as part of the study protocols for assessing adverse events. An analysis of these events showed outpatient visits for heart failure were substantially lower in participants who received empagliflozin compared with placebo.
Another limitation was the use of all-cause mortality as part of the primary endpoint, which meant that deaths unrelated to heart failure were included in the endpoint even though the study drug was unlikely to influence them. There were also some unusual circumstances that may have influenced rates of both hospitalization and death, including the COVID-19 pandemic and conflicts involving Russia, Ukraine and Israel, all countries that participated in the trial.
Finally, researchers said that the follow-up period may have been too short to fully capture any difference in mortality related to heart failure. Since people who developed heart failure following their heart attack typically did not begin to show heart failure symptoms until a few months later, any reductions in mortality would not be expected to emerge until after that.
We just did not have long enough follow-up to see whether that heart failure prevention would lead to a benefit in mortality, but its a reasonable clinical thing to say that if youre preventing heart failure, its a good thing, Butler said.
The study was funded by Boehringer Ingelheim and Eli Lilly.
This study was simultaneously published online in the New England Journal of Medicine at the time of presentation.
Butler presented the study, Empagliflozin After Acute Myocardial Infarction: Results of the EMPACTMI Trial, on day one of the 3-day ACC.24 conference.
For more information: http://www.acc.org
Find more ACC24 conference coverage here
More here:
SGLT-2 Inhibitors Show Mixed Results After Heart Attack - Diagnostic and Interventional Cardiology
- Capital Cardiology Associates and CDPHP at odds over withheld payments - Times Union - March 30th, 2025 [March 30th, 2025]
- Mar 28, 2025 This Week in Cardiology Podcast - Medscape - March 30th, 2025 [March 30th, 2025]
- Green Spaces and Heart Health: A Natural Connection - The Cardiology Advisor - March 30th, 2025 [March 30th, 2025]
- Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting - Business Wire - March 30th, 2025 [March 30th, 2025]
- SA Asks: What are the best large-cap cardiology stocks right now? - Seeking Alpha - March 30th, 2025 [March 30th, 2025]
- Introducing New Cardiology Members - University of Utah School of Medicine - March 30th, 2025 [March 30th, 2025]
- SA Asks: Which cardiology drug companies could be takeout candidates? - Seeking Alpha - March 30th, 2025 [March 30th, 2025]
- Teams at Stormont Vail Hospital heard firsthand from a leading expert and researcher in cardiology - WIBW - March 30th, 2025 [March 30th, 2025]
- ACC 2025: GE HealthCare announces the U.S. launch of pivotal innovations that will help transform the cardiology care pathway - Business Wire - March 30th, 2025 [March 30th, 2025]
- CONNEQT Health Launches Industry-First Cardiology Report to Bring Clinical Heart Health Insights Home - Fitt Insider - March 30th, 2025 [March 30th, 2025]
- Indian Cardiology Market Size Trends and Forecast by Application, Type, and Geography, Opportunity Analysis - openPR - March 30th, 2025 [March 30th, 2025]
- What are the Health Benefits of the DASH Diet Plan? - Cardiology - Health Matters - March 15th, 2025 [March 15th, 2025]
- Mar 14, 2025 This Week in Cardiology Podcast - Medscape - March 15th, 2025 [March 15th, 2025]
- ECU Health offers remote healthcare access for cardiology patients - WNCT - March 15th, 2025 [March 15th, 2025]
- Powers Health cardiology experts support Hearts of Hope campaign, explore innovative treatments to improve patient lives at free community event -... - March 15th, 2025 [March 15th, 2025]
- Cardiology groups urge Congress to take a stand after spending proposal fails to fix Medicare cuts - Cardiovascular Business - March 15th, 2025 [March 15th, 2025]
- Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology - PR... - March 15th, 2025 [March 15th, 2025]
- Broward Health Adds Pulsed Field Ablation Sytsem to Treat A-fib - Diagnostic and Interventional Cardiology - March 15th, 2025 [March 15th, 2025]
- Global Interventional Cardiology Devices Market Poised for Remarkable Growth, Set to Reach USD 36.9 Billion by 2032 | FMI FMIBlog - Future Market... - March 5th, 2025 [March 5th, 2025]
- MCCH earns cath lab accreditation by the American College of Cardiology - The Trib - March 5th, 2025 [March 5th, 2025]
- Feb 28, 2025 This Week in Cardiology Podcast - Medscape - March 5th, 2025 [March 5th, 2025]
- Ozempic and other GLP-1s are trending in Hollywood and cardiology departments - WGLT - March 5th, 2025 [March 5th, 2025]
- Detecting coronary inflammation on CT imaging could reshape preventive cardiology - Cardiovascular Business - March 5th, 2025 [March 5th, 2025]
- Global Surge in Heart Rhythm Disorders Sparks Call to Action - Diagnostic and Interventional Cardiology - March 5th, 2025 [March 5th, 2025]
- Fujifilm Expands Partnership with Hackensack Meridian Health Enabling Network-wide Use of State-of-the-Art Synapse Cardiology PACS Imaging System -... - March 5th, 2025 [March 5th, 2025]
- Behind the Walls of Cardiology: Where innovation meets compassion - Brunswick News - February 25th, 2025 [February 25th, 2025]
- Cardiology Team: Making a Difference in Your Heart - Southeast Georgia Health System - February 25th, 2025 [February 25th, 2025]
- Feb 21, 2025 This Week in Cardiology Podcast - Medscape - February 25th, 2025 [February 25th, 2025]
- Nuclear cardiology a nuclear perspective on matters of the heart - healthcare-in-europe.com - February 25th, 2025 [February 25th, 2025]
- Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat - Morningstar - February 25th, 2025 [February 25th, 2025]
- Shenango Cardiology Consultants Affiliates with Meadville Medical - businessjournaldaily.com - February 25th, 2025 [February 25th, 2025]
- Author balances romance writing with cardiology insights - Turn to 10 - February 25th, 2025 [February 25th, 2025]
- Providing Health Care in Conflict Zones: A Neurosurgeons Mission to Gaza - The Cardiology Advisor - February 3rd, 2025 [February 3rd, 2025]
- Jan 31, 2025 This Week in Cardiology Podcast - Medscape - February 3rd, 2025 [February 3rd, 2025]
- At Least 60% of Americans To Have Heart Disease By 2050, According To Alarming Study Cardiology Experts Offer Tips To Know This Heart Month -... - February 3rd, 2025 [February 3rd, 2025]
- FMC column: Prioritize preventative cardiology during American Heart Month in February - Lancaster Eagle Gazette - February 3rd, 2025 [February 3rd, 2025]
- Interventional Cardiology Joins The Match for First Time - Medscape - January 23rd, 2025 [January 23rd, 2025]
- Akron Childrens teams with Cincinnati Childrens on pediatric cardiology care - Crain's Cleveland Business - January 23rd, 2025 [January 23rd, 2025]
- FDA regulator examines AI's growing influence in cardiology - Cardiovascular Business - January 23rd, 2025 [January 23rd, 2025]
- Jan 17, 2025 This Week in Cardiology Podcast - Medscape - January 23rd, 2025 [January 23rd, 2025]
- Jan 10, 2025 This Week in Cardiology Podcast - Medscape - January 15th, 2025 [January 15th, 2025]
- UC Davis Health cardiology team is one of the first in the nation to use novel pVAD system - UC Davis Health - January 15th, 2025 [January 15th, 2025]
- Bethesda Health Clinic Receives $15,000 Grant from American Heart Associations Circle of Red to Enhance Cardiology Services - Gilmer Mirror - January 15th, 2025 [January 15th, 2025]
- Top in cardiology: Antipsychotic drugs prolong severe QT; intermittent fasting and death - Healio - January 1st, 2025 [January 1st, 2025]
- ICYMI: 'Exploding in population': Nampa hospital expansion to bring needed NICU, cardiology space - boisedev.com - January 1st, 2025 [January 1st, 2025]
- Dec 20, 2024 This Week in Cardiology Podcast - Medscape - December 23rd, 2024 [December 23rd, 2024]
- Samuel Family Cardiology to open medical office in Spring - Community Impact - December 23rd, 2024 [December 23rd, 2024]
- Top in cardiology: Impact of added sugar source on CVD risk; SGLT2, GLP-1 use after stroke - Healio - December 23rd, 2024 [December 23rd, 2024]
- Researchers Find Drinking Coffee May Help Prevent Mental Decline in People with AFib - Diagnostic and Interventional Cardiology - December 23rd, 2024 [December 23rd, 2024]
- Narrow-Moat Ionis Is Expanding Its Neurology and Cardiology Portfolio to Strengthen Its Moat - Morningstar - December 9th, 2024 [December 9th, 2024]
- Shaping the Future of Cardiology: Key Takeaways From AHA 2024 - AJMC.com Managed Markets Network - November 28th, 2024 [November 28th, 2024]
- Jennifer DuMond Joins Cardiology Associates of Schenectady - SPHP News - November 28th, 2024 [November 28th, 2024]
- Nov 22, 2024 This Week in Cardiology Podcast - Medscape - November 28th, 2024 [November 28th, 2024]
- Fujifilm to Highlight the Speed of Synapse VX for Mammography and Cardiology, Cloud-Native Architecture and AI-Driven Workflows at RSNA 2024 - The... - November 28th, 2024 [November 28th, 2024]
- Director of Cardiology Research and Practical Centre: in many respects we keep pace with worlds largest clinics - - - November 28th, 2024 [November 28th, 2024]
- AI breakthrough in healthcare to revolutionize cardiology and more - Eyewitness News 3 - November 20th, 2024 [November 20th, 2024]
- Lehigh Valley Heart and Vascular Institute Welcomes Two Cardiology Specialists - Lehigh Valley Health Network - November 20th, 2024 [November 20th, 2024]
- Nov 15, 2024 This Week in Cardiology Podcast - Medscape - November 20th, 2024 [November 20th, 2024]
- Noblestitch Suture-Mediated PFO Closure Yields Zero Recurrent Strokes in the largest cohort with Four-Year Study presented at the TCT cardiology... - November 20th, 2024 [November 20th, 2024]
- Centra Health shifting cardiology services from Danville to Gretna - GoDanRiver.com - November 20th, 2024 [November 20th, 2024]
- Interventional Cardiology Devices Market to Reach $33.46 Billion by 2031, Growing at a 7.5% CAGR As Reveale... - WhaTech - November 20th, 2024 [November 20th, 2024]
- Dr. Kathleen A. Harper, MD is featured as a TOP INDUSTRY EXPERT Representing the Field of Cardiology for 2024 - EIN News - November 20th, 2024 [November 20th, 2024]
- 'Exploding in population': Nampa hospital expansion to bring needed NICU, cardiology space - boisedev.com - November 12th, 2024 [November 12th, 2024]
- Cardiology Diagnostics Market: Rapid Growth and Key Research - openPR - November 12th, 2024 [November 12th, 2024]
- Oct 25, 2024 This Week in Cardiology Podcast - Medscape - October 26th, 2024 [October 26th, 2024]
- Cardiology of Virginia patient data appears to be up for sale. Has the entity issued any statement at all? - DataBreaches.net - October 26th, 2024 [October 26th, 2024]
- Philips showcases next level cardiology innovations for improved patient care at TCT 2024 - Yahoo Finance - October 26th, 2024 [October 26th, 2024]
- Care Medical and Boston Scientific to enhance cardiology and urology care - Healthcare Asia - October 26th, 2024 [October 26th, 2024]
- Is Cardiology Overtreating Aortic Stenosis? with Linda Gillam, MD, MPH - MD Magazine - October 13th, 2024 [October 13th, 2024]
- Oct 11, 2024 This Week in Cardiology Podcast - Medscape - October 13th, 2024 [October 13th, 2024]
- The need for a personalized implementation hypertension strategy to facilitate the implementation of the new European Society of Hypertension (2023),... - October 13th, 2024 [October 13th, 2024]
- Cardiology Information System Market Size Expected To Grow At Around 8.6% CAGR During The Forecast Period - openPR - October 2nd, 2024 [October 2nd, 2024]
- OSF Medical Group in Alton Welcomes Second Cardiology Nurse Practitioner Mary Goetten - RiverBender.com - October 2nd, 2024 [October 2nd, 2024]
- Top in cardiology: Heart attacks spike after cold spells; Wegovy linked to CV benefits - Healio - October 2nd, 2024 [October 2nd, 2024]
- The Potential Risks of Lecanemab Use in Patients With High Cardiovascular Risk - The Cardiology Advisor - October 2nd, 2024 [October 2nd, 2024]
- $41,900.3+ Mn Interventional Cardiology and Peripheral Vascular Devices Market: Rising Demand and Growth - EIN News - October 2nd, 2024 [October 2nd, 2024]
- Central Pa. cardiology practice relocates one of its offices - PennLive - October 2nd, 2024 [October 2nd, 2024]
- Emerging Therapies in Interventional Cardiology - ETHealthWorld - October 2nd, 2024 [October 2nd, 2024]
- Sep 20, 2024 This Week in Cardiology Podcast - Medscape - September 23rd, 2024 [September 23rd, 2024]
- 'An exciting time': PCB medical office building adds cardiology and pulmonary services - The News Herald - September 23rd, 2024 [September 23rd, 2024]